‘Twincretin’ Tirzepatide Gets FDA Approval for Type 2 Diabetes
The “Twincretin” era for treating patients with type 2 diabetes has begun, with the US Food and Drug Administration’s (FDA’s) approval of tirzepatide for this indication on May 13, making it the first approved agent that works as a dual agonist for the two main human incretins. Tirzepatide represents “an important advance in the treatment … Read more